SALT LAKE CITY

Calibre’s Q1 Gold Production on Track to Deliver Full Year 2024 Guidance While Advancing Operational Readiness For H1, 2025 First Gold at The Fully Funded Valentine Gold Mine

Retrieved on: 
Tuesday, April 9, 2024
Consolidated, Growth, Gold, ETW, Acquisition, Indication (medicine), TSX, Mineral, CXB, OTCQX, VGM, Process, Reserve, Van Eck, Palladium

We remain on track to deliver full year 2024 production guidance of 275,000 – 300,000 ounces.

Key Points: 
  • We remain on track to deliver full year 2024 production guidance of 275,000 – 300,000 ounces.
  • Since becoming a gold producer during Q4, 2019, Calibre has delivered annual production growth of 28% year on year, with a track record of meeting or beating expectations.
  • 2024 and 2025 will be transformational years, driven by an increase in gold production and significant exploration across the Americas.
  • I am pleased to report the final phases of construction and operational readiness remain on track and fully funded at VGM in preparation for first gold production in H1, 2025 to unlock significant production growth and value for our shareholders.

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

Retrieved on: 
Tuesday, April 9, 2024
MYGN, Genetics, Overalls, Medicine, Patient, Myriad Genetics, Cohort (statistics), Genetic testing, DSM-IV codes, Pharmaceutical industry

(NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .

Key Points: 
  • (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test .
  • “We are encouraged by the initial results of this study that showed how the proportion of patients with hospitalizations was significantly reduced after GeneSight testing,” said Dale Muzzey, chief scientific officer, Myriad Genetics.
  • We expect to share additional study results later this year.”
    The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing:
    39% relative reduction in psychiatric-related hospitalizations.
  • Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions.

Leading National Massage Experience Squeeze Appoints Brian Boucher as Chief Operating Officer

Retrieved on: 
Monday, April 8, 2024
Partner, Culture, Organization, Planet Fitness, Overalls, Operating partner, Massage

Nashville, TN, April 08, 2024 (GLOBE NEWSWIRE) -- Squeeze , the fast growing massage experience from the founders of Drybar, announced today that Brian Boucher has been named the company’s Chief Operating Officer (COO), effective immediately.

Key Points: 
  • Nashville, TN, April 08, 2024 (GLOBE NEWSWIRE) -- Squeeze , the fast growing massage experience from the founders of Drybar, announced today that Brian Boucher has been named the company’s Chief Operating Officer (COO), effective immediately.
  • Bringing more than 20 years of operations experience to Squeeze, Boucher will oversee the company’s operational efficiencies to drive brand growth, in addition to implementing new initiatives to support Squeeze’s best-in-class franchise system.
  • "We are thrilled to welcome Brian as our newly appointed COO,” said Brittany Driscoll, Squeeze Co-Founder & CEO.
  • Brian Boucher is succeeding David Werner, who will be transitioning into the role as Squeeze’s Chief Product Officer.

Global Volunteering Summit 2024: Goodera Unveils Breakthroughs in Corporate Volunteering

Retrieved on: 
Friday, April 5, 2024
Quotient, Organization, ESG, SAN, Public utility, Conspiracy, API, Summit, University of Oxford, Deed, Tourism

The Global Volunteering Summit served as a platform for social impact executives from over 100 renowned organizations to connect with peers, deepen their understanding of volunteering's impact, and explore the vital role of technology in social innovation through volunteering.

Key Points: 
  • The Global Volunteering Summit served as a platform for social impact executives from over 100 renowned organizations to connect with peers, deepen their understanding of volunteering's impact, and explore the vital role of technology in social innovation through volunteering.
  • At the Summit, Goodera also announced innovative solutions to create actionable, positive change:
    Goodera launched its first Volunteering Quotient Report , offering insights into volunteering initiatives across 162 company ESG and annual reports that revealed:
    Average Volunteering Hours: Corporate volunteers contribute an average of 6.8 hours through their organizations.
  • Impact of Volunteering Enablers: Companies offering employees volunteering enablers such as ‘Dollars for doers’, volunteering time off, or a volunteering platform exhibit, on average, ~1.5 times higher volunteer participation rates.
  • "The Global Volunteering Summit '24 represented a watershed moment for both Goodera and the volunteerism movement, uniting our community to showcase the power of collective action, innovation, and technology.” said Abhishek Humbad, Founder and CEO of Goodera.

Leash Biosciences Announces $9.3 Million Seed Financing to Pioneer AI-Driven Medicinal Chemistry

Retrieved on: 
Friday, April 5, 2024
Drug design, Biotechnology, Drug discovery, Artificial intelligence, Stripe, Myriad Genetics, Protein folding, Biology, Data collection, Chemistry, Therapy, Machine learning, Data, Leash, Collection

SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection. The oversubscribed round was led by Springtide Ventures with participation from MetaPlanet, Top Harvest Capital, Mitsui Global Investment, MFV Partners, Recursion CEO and co-founder Chris Gibson, and Recursion co-founder Blake Borgeson.

Key Points: 
  • SALT LAKE CITY, April 05, 2024 (GLOBE NEWSWIRE) -- Leash Biosciences, an artificial intelligence and machine learning (AI/ML)-native biotechnology company unleashing machine learning to solve medicinal chemistry, today announced the completion of a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection.
  • To achieve this, Leash is producing bespoke, expansive datasets of protein targets binding to chemicals.
  • We believe a similar strategy will revolutionize how we approach medicinal chemistry," said Ian Quigley, CEO of Leash Biosciences.
  • "Leash's platform stands apart with its combined excellence in machine learning, experimental biology, and medicinal chemistry," said Claire Smith, Lead Investor at Springtide Ventures.

SINTX Technologies Announces Pricing of $1.5 Million Public Offering of Common Stock

Retrieved on: 
Wednesday, April 3, 2024
Form, Telephone, Sale, Attention, Prospectus

SALT LAKE CITY, UT, April 03, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced the pricing of its previously announced public offering of 71,600,000 shares of its common stock at a public offering price of $0.021 per share.

Key Points: 
  • SALT LAKE CITY, UT, April 03, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced the pricing of its previously announced public offering of 71,600,000 shares of its common stock at a public offering price of $0.021 per share.
  • Gross proceeds from the offering are expected to be approximately $1.5 million before deducting placement agent fees and estimated offering expenses.
  • SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes.
  • The public offering is being made pursuant to an effective shelf registration statement on Form S-3, as amended (File No.

Recursion to Participate in Upcoming Investor Conference

Retrieved on: 
Tuesday, April 2, 2024
Biology, Conference, Drug discovery

SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference:

Key Points: 
  • SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference:
    23rd Annual Needham Virtual Healthcare Conference – April 8-11, 2024

Security National Financial Corporation Reports Financial Results for the Year Ended December 31, 2023

Retrieved on: 
Monday, April 1, 2024
SNFC, Tax, Growth, Environment, Mortality, Acquisition, Death

SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- Security National Financial Corporation (SNFC) (NASDAQ symbol "SNFCA") announced financial results for the year ended December 31, 2023.

Key Points: 
  • SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- Security National Financial Corporation (SNFC) (NASDAQ symbol "SNFCA") announced financial results for the year ended December 31, 2023.
  • For the twelve months ended December 31, 2023, SNFC’s after-tax earnings from operations decreased 44% from $25,690,000 in 2022 to $14,495,000 in 2023, on a 18% decrease in revenues to $318,497,000.
  • Scott Quist, Chairman of the Board, President, and Chief Executive Officer of SNFC, said, “2023 was a year where the financial balance of our company demonstrated itself.
  • The following table shows the revenues and earnings before taxes for the twelve months ended December 31, 2023, as compared to 2022, for each business segment:

SINTX Technologies Announces Proposed Public Offering of Common Stock

Retrieved on: 
Friday, March 29, 2024
Form, Telephone, Sale, Attention, Prospectus, Form S-3

SALT LAKE CITY, UT, March 29, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering.

Key Points: 
  • SALT LAKE CITY, UT, March 29, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, today announced that it intends to offer and sell shares of its common stock in a public offering.
  • All shares of common stock in the offering are to be offered by SINTX.
  • SINTX intends to use the net proceeds of the offering, if any, for working capital and general corporate purposes.
  • Maxim Group LLC is acting as sole placement agent, on a reasonable best efforts basis, for the proposed offering.

Calibre Enters Pre-Commissioning and Commissioning Contract with Reliable Controls Corporation and Executes A Gold Prepayment

Retrieved on: 
Thursday, March 28, 2024
Gold, TSX, CXB, OTCQX, RCC, Rio Tinto, Valentine

Darren Hall, President and Chief Executive Officer of Calibre, stated: “With construction at Valentine 61% complete I remain confident in our ability to deliver first gold during H1, 2025.

Key Points: 
  • Darren Hall, President and Chief Executive Officer of Calibre, stated: “With construction at Valentine 61% complete I remain confident in our ability to deliver first gold during H1, 2025.
  • To further derisk delivery, I am pleased to announce that we have secured RCC, a team of highly experienced commissioning experts to lead pre-commissioning and commissioning of the process plant.
  • Calibre is required to deliver Asahi 2,300 ounces of gold per month over a twelve-month period, beginning in May 2024, such ounces determined based on gold forward curve prices averaging $2,239 per ounce.
  • Approximately 2,233 ounces per month will be credited against the prepayment and Calibre will receive a cash payment for the balance.